L’Oréal, a global leader in the beauty industry, has announced a strategic partnership with Tru Diagnostic, a pioneer in epigenomics testing. This collaboration seeks to explore the relationship between beauty indicators and changes in epigenomic markers, unlocking new possibilities for advancements in the science of longevity.
With more than 100 years of expertise in skin and hair biology, L’Oréal is positioned to lead this transformative research alongside Tru Diagnostic, an authority in epigenetics. Through this partnership, the two companies will conduct innovative studies aimed at uncovering the complex links between epigenetics and beauty. The goal is to develop products that not only enhance aesthetic appeal but also promote long-term skin and hair health, reflecting the emerging field of longevity science.
Guive Balooch, Head of Open Innovation and Augmented Beauty at L’Oréal, highlighted the significance of the partnership: “This collaboration marks a key milestone for us. By combining our deep understanding of beauty biology with Tru Diagnostic’s expertise in epigenomics, we are poised to make breakthrough discoveries in longevity biomarkers. Our goal is to provide consumers with proactive solutions for skin and hair health based on the latest longevity science.”
Matthew Dawson, CEO of Tru Diagnostic, expressed his enthusiasm, stating: “We are excited to partner with L’Oréal to explore how epigenetic markers influence beauty. Epigenomics offers revolutionary insights into beauty at a biological level. Together, we aim to integrate this science into the beauty industry, creating products that reflect the future of beauty and longevity.”
This strategic alliance underscores both companies’ commitment to pioneering research and innovation in the emerging field of longevity within the beauty sector. By leveraging the science of epigenetics, L’Oréal and Tru Diagnostic aim to deliver groundbreaking solutions that promote beauty from within, offering consumers comprehensive approaches to skincare and haircare.
About L’Oréal
For over 115 years, L’Oréal has been a global leader in beauty, with a mission to fulfill the beauty aspirations of consumers worldwide. Known for its broad portfolio of 37 international brands, L’Oréal is dedicated to social and environmental sustainability through its “L’Oréal for the Future” program. With more than 90,000 employees and operations in over 150 countries, the company generated 41.18 billion euros in sales in 2023. L’Oréal’s research and innovation efforts are powered by a team of over 4,000 scientists working across 20 research centers globally.
About Tru Diagnostic
Tru Diagnostic is a leading company specializing in epigenomics testing. Its advanced technology provides valuable insights into how epigenetic changes influence health and well-being, enabling individuals to make informed decisions about their health and beauty.
For more information, visit www.loreal.com.
This press release is for informational purposes only and does not constitute an offer to buy or sell L’Oréal shares. For additional financial details, please refer to the documents registered with the French Autorité des Marchés Financiers, available on the company’s website.
Related Topics
